ABSTRACT
Methods: A retrospective chart review was conducted for patients (n = 140) in whom laboratory testing for HIT was requested. 4Ts scores were calculated and correlated with heparin-endogenous platelet factor 4 antibody enzyme-linked immunosorbent assay (ELISA) test results.

Results: All patients with a high pretest probability of HIT (4Ts score = 6-7) had positive ELISA results, compared to 26.1% of patients with intermediate (4Ts score = 4-5) and 4.3% of patients with low (4Ts score ≤3) pretest probability. No patients with 4Ts scores of 2 or less had positive ELISA results.
Conclusions: HIT can be ruled out in cancer patients
(negative predictive value and sensitivity = 100%) with low pretest probability, defined by 4Ts scores of 2 or less, significantly reducing the need for laboratory testing in this patient population.
Heparin-induced thrombocytopenia (HIT) is a potentially lethal complication of therapy with unfractionated heparin or its derivatives. 1, 2 HIT is caused by the development of antibodies directed against a molecular complex formed when heparin associates with endogenous platelet factor 4 (PF4). The formation of the heparin-PF4 immune complex leads to activation of platelets, monocytes, and endothelial cells with subsequent release of procoagulant proteins and tissue factor. 1, [3] [4] [5] The incidence of HIT has been reported to range from 0.1% to 5% in hospitalized patients exposed to unfractionated heparin. 2, 6 HIT is a hypercoagulable state that can cause severe venous and arterial thromboembolic complications in patients. These complications may be associated with significant morbidity and even mortality. Mortality has been reported as high as 30% in patients with HIT and HIT thrombosis. 1 The diagnosis of HIT is based on clinical assessment and laboratory documentation of heparin-dependent antibodies. In patients exposed to heparin, immune reactions to heparin-PF4 complexes are relatively common, varying from 8% to 50%, whereas clinical complications are rare at 0.2% to 3%. 7 To avoid overdiagnosis of HIT, various scoring systems have been developed to help assess the pretest probability of HIT in patients. These scoring systems include the 4Ts score, the Lillo-Le Louёt model, and the HIT expert probability score. 8, 9 The 4Ts score is a well-validated method used as a standardized approach to determine the pretest probability of HIT. 2, 10 This score is especially useful to exclude HIT given its high negative predictive value of 99.8%. 10, 11 Laboratory tests to help diagnose HIT include enzyme-linked immunosorbent assays (ELISA) that detect heparin-PF4 antibodies and platelet function assays such as the serotonin release assay (SRA), which is considered the gold standard in HIT testing. The SRA measures the ability of heparin-PF4 immune complexes to activate normal donor washed platelets that were exposed to 14 C-serotonin. 2, 12 Laboratory screening tests such as the ELISA are highly sensitive to the presence of antibodies recognizing heparin-PF4 complexes, but their lack of specificity may cause false-positive test results that require further investigation. An optical density (OD) of 0.4 or greater is considered a positive ELISA result. The degree of positivity correlates with the likelihood of HIT in patients. A patient with an OD of less than 1.0 is less likely to develop HIT. 13, 14 Using the 4Ts scoring system to assess pretest probability can reduce the incidence of false-positive screening test results.
In this study, we evaluated the utility of the 4Ts scoring system in a cancer patient population to determine whether a 4Ts score could be used to guide subsequent ordering of HIT laboratory screening tests by clinicians. There is a paucity of information focusing on HIT in cancer patients. Prandoni et al 15 found that patients with cancer develop HIT more frequently than those without cancer. Given that cancer patients often have thrombocytopenia from various causes (eg, malignancy itself, chemotherapy, antibiotic therapy, and hematopoietic stem cell transplantation), we aimed to identify a 4Ts score cutoff value that would enable clinicians to determine if laboratory testing for HIT was indicated and optimize utilization of laboratory screening tests.
Materials and Methods
Data Collection
A retrospective chart review was conducted for all patients with laboratory testing for HIT performed from February 2015 to October 2015 and February 2016 to March 2016. Study patients included hospitalized and clinic patients at Memorial Sloan Kettering Cancer Center. Individual 4Ts scores were calculated by a laboratory medicine fellow from clinical information obtained during chart review of the patients' medical records. The 4Ts score is based on four parameters, including: (1) the degree of thrombocytopenia, (2) the timing of platelet count decline relative to heparin exposure, (3) the presence of thrombosis, and (4) the absence of other explanations for thrombocytopenia. Each parameter is given a point value from 0 to 2, and points are added for a maximum possible score of 8 ❚Table 1❚. 7 The 4Ts score is then used to assign pretest probability of HIT, with scores representing high (6-8), intermediate (4) (5) , or low (0-3) pretest probability. 7, 16 Each patient's 4Ts score was correlated with results of the corresponding heparin-PF4 IgG ELISA screening test.
Heparin-PF4 Antibody Test
Heparin-PF4 HIT antibodies (IgG) were detected using the GTI-PF4 ELISA Kit (GTI Diagnostics, Waukesha, WI) according to the manufacturer's guidelines, using an OD cutoff value of 0.4 units. The heparin-PF4 ELISA includes a confirmatory test on all samples run using excess heparin to increase specificity. At our institution a positive test result is reported when the OD value is 0.4 or greater and inhibition by heparin exceeds 50%. A test result is interpreted as equivocal when the OD value is less than 0.8 and/or inhibition by heparin is less than 50%. Confirmatory testing by SRA is performed at the discretion of the ordering health care provider.
Statistics
Statistical analyses were performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La 
Results
The 4Ts scores were correlated with HIT ELISA screening test results in a total of 140 patients. Study patient demographics and diagnoses are summarized in ❚Table 2❚. There was a roughly equal distribution of male and female patients, and most patients had solid organ malignancies. The 4Ts score distribution for all patients is shown in ❚Figure 1❚. Most patients (82.1%) had 4Ts scores suggesting a low probability of HIT (4Ts score = 0-3), whereas only 16.4% and 1.4% of patients had 4Ts scores suggesting an intermediate (4Ts score = 4-5) or high (4Ts score = 6-8) pretest probability of HIT, respectively.
Additionally, shown in ❚Figure 2❚ is the correlation between 4Ts scores and heparin-PF4 IgG ELISA screening test results. A positive screening test result was defined by an OD of 0.4 units or greater, according to manufacturer's instructions. HIT ELISA test results were negative (OD < 0.4) in 90.7% (n = 127) of patients. Each of two patients (2/2) with a high pretest probability of HIT (4Ts scores = 6 and 7) had a positive ELISA test result (OD units 1.193 and 3.025, respectively). In comparison, 26.1% (6/23) of patients with an intermediate pretest probability of HIT (4Ts score = 4 and 5) had positive ELISA test results (OD units ranging from 0.698 to 2.806). Only 4.3% (5/115) of patients with a low pretest probability of HIT (4Ts score ≤3) had positive ELISA test results (OD units ranging from 0.418 to 2.506). Of note, no patients with a 4Ts score of 2 or less had a positive HIT ELISA test result.
Discussion
HIT is a potentially lethal complication of therapy with unfractionated heparin or its derivatives. 1,2 Although many studies have been published on HIT, there is a paucity of literature focusing on cancer patients. Our findings help fill a void in the literature by suggesting a new low probability 4Ts score for HIT in cancer patients. A redefinition of the HIT 4Ts scoring is indicated in our cancer a Other included patients with polycystic kidney disease, benign granulomatous upper airway lesion, interstitial lung disease, and a patient with concurrent germ cell tumor and chronic myelomonocytic leukemia.
❚Figure 1❚ Distribution and correlation of 4Ts scores and heparin-induced thrombocytopenia (HIT) enzyme-linked immunosorbent assay (ELISA) screening test results. Pretest probability of low, intermediate, and high risk for HIT correlate with 4Ts score of 0-3, 4-5, and 6-7, respectively. patients as many are undergoing treatment regimens that affect platelet counts, lowering the maximum possible 4Ts score from 8 to 6. We aimed to set up a 4Ts score cutoff value that would allow for better utilization of HIT ELISA testing and eliminate unnecessary testing.
These data suggest that low probability for HIT in cancer patients may be defined by a 4Ts score of 0 to 2, compared to the traditional cutoff 4Ts score of 0 to 3 ❚Table 3❚. Based on the current patient cohort, this newly defined low-risk pretest probability 4Ts score rules out a positive ELISA test result with a high negative predictive value of 100% (95% confidence interval [CI], 75%-100%) and a sensitivity of 100% (95% CI, 95%-100%) ❚Table 4❚, thereby eliminating subsequent laboratory testing in these individuals. In this study population, restricting HIT ELISA screening to cancer patients with 4Ts scores greater than 2 would have reduced laboratory testing by 47.9% (67/140), achieving substantial conservation of clinical and laboratory resources. At our institution, these findings serve as an educational tool for clinicians.
Our observation that a 4Ts cutoff score of 2 or below was consistently associated with a negative HIT antibody titer (OD < 0.4), and may be used safely to discourage laboratory screening for HIT by high-sensitivity/low-specificity ELISA tests. Additionally, one year follow-up chart review showed that no patients with screening ELISA test results of OD 0.4 or greater and less than 0.8 were considered to have HIT clinically. This finding is supported by a recently published study by Wong et al, 17 who recommended an optimal cutoff 4Ts score for HIT diagnosis in cancer patients of 5 instead of the traditionally recommended score of greater than 3, as well as an optimal cutoff heparin-PF4 polyclonal ELISA OD of 1.004. 17 Given the retrospective nature of the present study, positive HIT screening test results could not be confirmed with functional assays, such as serotonin release. This limits revision of the 4Ts scoring system to associations with negative ELISA screening test results. Additional limitations include few positive cases and limited duration of data collection, which correlates with the dates the laboratory medicine fellow was on the coagulation service.
At our institution, a significant number of ELISA screening test orders to detect heparin-PF4 IgG are for patients with low calculated 4Ts scores (≤2). This phenomenon has been described in previous studies in noncancer patients. 10, 18 Utilizing a revised 4Ts scoring system has the potential to reduce laboratory screening in approximately 50% of our patients and to provide a rapid clinical rule-out for HIT.
Unnecessary laboratory testing for HIT is associated with an increase in potential false-positive test results that drives needless changes in anticoagulation therapy and increases length of stay for patients, all contributing to increased health care costs. Additionally, inappropriate use of laboratory resources, including technologist time and reagents, drains resources. Implementation of pretest 4Ts scoring would enhance cancer patient care and conservation of clinical laboratory resources. In the accountable care era, it is important to establish and implement appropriate clinical guidelines to eliminate unnecessary laboratory testing. 
